Validation by Numbers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Validation by Numbers
A book helps statistics novices prepare to comply with the US Food and Drug Administration's draft guidance on process validation.


Pharmaceutical Technology
Volume 34, Issue 5


Validation by Design, Lynn Torbeck, PDA Books, Bethesda, MD, 2010, 200 pp., ISBN: 193372238X
How many samples should I take? Is the assay method validated? Is this result really out of specification? Should I adjust the tablet weight? Is this process under control? Should I reject the batch? The pharmaceutical industry has always faced questions such as these, and they may be answered best from a statistical perspective.

Unfortunately, many quality-assurance workers and production managers charged with answering these types of questions do not have an adequate working knowledge of statistics. They find it difficult to answer these questions and to understand answers that statisticians provide.

The book Validation By Design: The Statistical Handbook for Pharmaceutical Process Validation, by Lynn Torbeck, a member of Pharmaceutical Technology's Editorial Advisory Board, contains information useful to people who are new to statistics and to employees responsible for implementing statistical techniques that monitor and control pharmaceutical production processes and quality-assurance activities. The book was written specifically to address the statistical issues contained in the US Food and Drug Administration's November 2008 draft guidance for industry titled Process Validation: General Principles and Practices, which is reproduced in its entirety in an appendix. Torbeck's book can form the basis for interdepartmental discussions and for an understanding of the statistical techniques that are consistent with the intent of the guidance.

An important feature of the book is its interpretation of the guidance's statistical implications. The author rewrote the guidance's statistical content as a series of self-audit questions that cite specific lines in the guidance document. For example, lines 27–29 of the guidance state, "The lifecycle concept links the product and process development, qualification of the commercial manufacturing process, and the maintenance of the process in a state of control during routine commercial production." The associated self-audit question asks, "Is the process in a state of control during routine commercial production?" The question is followed

by a brief explanation of the term "state of control" and a reference to the chapter of the book that describes the concept. This self-audit format leads the reader through the various statistical techniques that enable compliance with various sections of the guidance.

A second important feature of the book is the chapters that elucidate statistical methods and concepts. Each of these chapters is written in a standard format that contains subtopics such as "Other Names," "Acronyms," "Definition," "Related Topics," "Calculation," "Illustration," "Cautions," "Advice," and "References." This consistent categorization enables the reader to understand the statistical concepts and decide whether their use is appropriate in a particular situation. The chapters explain simple statistical concepts such as average and relative standard deviation, as well as complicated ones such as control charts, root-cause analysis, process mapping, interquartile range, and Plackett–Burman designs.

The book should prove useful to employees charged with developing a self-audit program to measure the company's level of compliance with the process-validation guidance. It also would be a solid basis for writing validation protocols.

The book cannot be considered an introductory text about statistics because the topics are not presented in depth. Still, its references provide necessary information for readers who wish to delve further into any of the subjects. According to the author's preface, the book is for "those engaged in meeting the requirements of the FDA process-validation guidance." The questions that interpret the guidance, the author's explanations, and the chapters about statistical methods and techniques should do much to help personnel meet those requirements.

Russell Madsen is president of The Williamsburg Group, 18907 Lindenhouse Rd., Gaithersburg, MD 20879, tel. 301.938.4266, fax 301.869.5016,
. He also is a member of Pharmaceutical Technology's Editorial Advisory board.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here